SSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences Consultancy

Combination Creates a Leading, Integrated Provider of Drug Development and Regulatory Consulting Services Serving a Complementary Client Base

SSI Strategy (“SSI” or the “Company”) a leading Life Sciences consultancy, today announced that it has entered into a definitive agreement to acquire NDA Group AB (“NDA Group”), a leading regulatory affairs and drug development consultancy.

This strategic combination will create a premier consultancy, specializing in guiding drug development companies from concept to commercialization, helping optimize the development process and maximize the therapeutic value of complex and novel treatments.

The merger marks an exciting milestone following years of successful collaboration across numerous clients, resulting in the launch of the most innovative therapies available in the world today.

Financial terms of the transaction were not disclosed.

SSI is a premier Life Sciences consultancy that has been working with clients to accelerate all stages of drug development since 2007. SSI’s core competencies include clinical development, translational medicine, clinical operations, medical affairs, pharmacovigilance, health economics and outcomes research (HEOR), and real-world evidence (RWE) services. With a team of experts spanning the U.S. and Europe, the Company works closely with drug development clients to provide an innovative and bespoke support model including embedding fully functional teams. SSI’s R&D experts and clinicians partner with clients to close gaps and achieve objectives across the drug development landscape. In December 2020, SSI partnered with Amulet Capital Partners, a middle-market private equity investment firm focused exclusively on the healthcare sector, to fuel its expansion and grow its capabilities in adjacent Life Sciences functions.

Founded in 1997, NDA Group has an extensive presence across the EU, UK, Switzerland, and the U.S. For over 25 years, NDA Group has provided the life science industry with unmatched regulatory expertise, ensuring that they meet the rigorous demands of the regulatory agencies. The team at NDA Group comprises over 100 ex-regulators, industry experts and highly experienced consultants dedicated to helping drug developers make the right decisions to secure the safest and most efficient pathway to approval for their products.

“NDA Group is regarded as the premier regulatory consultancy for Life Sciences companies across the U.S. and Europe, and we’re delighted to build upon our longstanding partnership with this combination,” said Doug Locke, Chief Executive Officer of SSI Strategy. “This transaction brings together two highly regarded consultancies to create an integrated, end-to-end provider of drug development and regulatory consulting services. Combined, we will provide our common client base with best-in-class clinical development and regulatory expertise. Over years of collaboration between our businesses, we have proven our ability to execute together and are confident the success we have shared on prior partnerships will translate into more value for our clients from day one.”

Johan Strömquist, CEO of NDA Group, commented, “SSI’s unparalleled combination of business acumen and medical expertise has formed a unique space in the Life Sciences market. We are excited to join forces with them to expand upon this platform together. While NDA Group has been a world leading regulatory development consultancy for the past 25 years, there are still challenges that biotechs face that we have not been able to fully address. Together with SSI, we can not only optimize the regulatory path, but now also partner with our clients to execute the entire development program. For our clients, this will mean reduced risk, reduced costs, increased success rates and faster time to market. For the patient, this means higher quality treatments without unnecessary delay.”

Avi Uttamchandani, Principal at Amulet added, “Together, SSI and NDA will create a leading Life Sciences and drug development consultancy positioned to support both emerging and established biotechnology companies at every stage of the drug development and approval process. This combination will significantly enhance SSI’s regulatory support services and grow its industry leading team of experts while positioning the Company to grow its geographic footprint and expand its presence serving clients across the U.S. and Europe.”

Following the close of the transaction, NDA will operate as a strategic business unit (SBU) under SSI. SSI Strategy President Adam Schwartz will continue to lead SSI’s operations while the NDA management team will continue leading the NDA SBU under the guidance of President Johan Strömquist.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.